Organization Profile

You just read:

Bristol-Myers Squibb announces high cure rates for genotype 3 hepatitis C using combination of daclatasvir and sofosbuvir in ALLY-3 trial

News provided by

Bristol-Myers Squibb Canada

Nov 13, 2014, 05:59 ET